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Abstract
Objectives:	Restless	legs	syndrome	(RLS)	can	lead	to	severe	clinical	consequences,	
thus	negatively	impacts	on	patients’	overall	health	and	quality	of	life.	Nevertheless,	
the	pathophysiology	of	RLS	is	still	unclear,	resulting	in	underestimate,	incorrect,	or	
ignored diagnosis and in limited management and treatment. The aim of this study 
was	to	compare	the	plasma	proteome	of	RLS	patients	and	healthy	controls,	 in	the	
search of diagnostic biomarkers related to the disease severity.
Materials and Methods:	 Two-	dimensional	 gel	 electrophoresis	 coupled	 with	 liquid	
chromatography-	mass	spectrometry	was	employed	to	analyze	plasma	samples	of	34	
patients	with	primary	RLS,	divided	into	two	subgroups	according	to	the	disease	se-
verity:	MMS	group	(mild-	moderate	symptoms)	and	HS	group	(severe	and	very	severe	
symptoms),	 and	17	 age-	 and	 sex-	matched	 control	 subjects.	 Sleep	quality,	 daytime	
sleepiness,	and	the	level	of	depression	were	also	evaluated.
Results:	We	 identified	eight	upregulated	 spots,	 corresponding	 to	 five	unique	pro-
teins,	 in	both	RLS	group	vs.	controls	(alpha-	1B-	glycoprotein,	alpha-	1-	acid	glycopro-
tein	 1,	 haptoglobin,	 complement	C4-	A,	 and	 immunoglobulin	 kappa	 constant);	 five	
increased	spots,	consistent	with	three	unique	proteins,	only	in	HS-	RLS	(kininogen-	1,	
immunoglobulin	heavy	constant	alpha	1,	 and	 immunoglobulin	 lambda	constant	2);	
one	downregulated	spot	in	both	patient’s	groups	(complement	C3)	and	another	one	
only	in	HS-	RLS	(alpha-	1-	antitrypsin).
Conclusions:	The	significantly	different	plasma	proteins	detected	in	RLS	were	mainly	
associated	 with	 inflammation,	 immune	 response,	 and	 cardiovascular	 disorders.	
Particularly,	the	gradual	increasing	in	immunoglobulins	could	be	indicative	of	the	dis-
ease	severity	and	evolution.	Accordingly,	these	proteins	may	represent	a	valid	set	of	
useful	biomarkers	for	RLS	diagnosis,	progression	and	treatment.
K E Y W O R D S
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1  | INTRODUC TION
Restless	 legs	 syndrome	 (RLS),	 also	 called	Willis–Ekbom	disease,	 is	
a neurological sensorimotor condition characterized by unpleasant 
sensations	in	the	legs,	which	leads	to	the	pressing	need	to	move	the	
limbs,	thus	relieving	the	associated	discomforts,	such	as	paresthesias	
and	dysesthesias	(Allen	et	al.,	2003).	These	symptoms	occurring	at	
rest	 and	 their	 intensity	 increase	 in	 the	 evening	or	 night,	 often	 in-
ducing	spontaneous	episodic	jolting	of	the	legs	that,	 in	turn,	cause	
serious	sleep	disruption	and	impairs	quality	of	life	(Trotti,	2017).
It	is	estimated	that	RLS	prevalence	is	higher	in	Europe	and	North	
America,	ranging	from	5%	to	10%,	and	lower	in	Asia,	where	it	affects	
approximately	1%–7%	of	the	adult	population.	Moreover,	the	preva-
lence increases with age and it is suggested that the syndrome is also 
associated	with	female	sex,	low	socioeconomic	status,	smoking,	fre-
quent	alcohol	consumption,	 low	education,	and	unhealthy	 lifestyle	
(Didriksen	et	al.,	2017).
Additionally,	 recent	studies	have	shown	some	risk	factors	con-
nected	to	RLS,	such	as	coronary	heart	disease	 (Li	et	al.,	2012)	and	
other	complications	that	can	cause	or	worsen	RLS,	for	example,	di-
abetic	neuropathy	 (Gemignani,	Brindani,	&	Marbini,	2008),	chronic	
kidney	disease(Novak,	Winkelman,	&	Unruh,	 2015),	 and	 iron	 defi-
ciency	(Connor,	2008),	as	well	as	various	consequences	of	the	syn-
drome,	 such	as	 insomnia,	 anxiety,	 and	depression	 (Earley	&	Silber,	
2010).
To	date,	 the	pathophysiology	of	primary	RLS	 is	still	 largely	un-
known,	 although	 dysfunctions	 in	 the	 dopaminergic	 system	 are	
suspected to have a role in its development. In support of this as-
sumption is that the current agents of choice for moderate- to- severe 
RLS	are	non-	ergot-	derived	dopamine	receptor	agonists,	even	if	aug-
mentation is a known complication of dopaminergic medications 
(Nagandla	&	De,	2013).
Although	 RLS	 has	 gained	 notable	 consideration	 in	 the	 last	
20	years,	the	diagnosis	is	still	predominantly	based	on	clinical	fea-
tures	and	the	use	of	self-	administered	questionnaires,	focused	on	
the	four	essential	diagnostic	criteria,	that	however	are	insufficient	
for	a	reasonably	valid	and	complete	RLS	assessment	(Allen	et	al.,	
2003).	Nowadays,	 there	are	no	standardized	diagnostic	 tests	 for	
RLS;	poor	 recognition	or	 strange	description	of	 symptoms	often	
causes	 delay	 in	 the	 diagnosis	 or,	 even	worse,	 in	misdiagnosis	 of	
RLS,	 resulting	 in	undertreatment	which,	 consequently,	 can	 leads	
to	severe	risk	of	metabolic	deregulation,	autonomic	dysfunction,	
and	cardiovascular	morbidity	(Nagandla	&	De,	2013).	Therefore,	a	
correct	diagnosis	and	an	appropriate	management	of	RLS	are	very	
important.	Particularly,	 to	 further	prevent	morbidity,	RLS	should	
be	diagnosed	in	early	stage.	In	this	way,	a	valid	help	for	the	iden-
tification of novel diagnostically relevant biomarkers can derive 
from	proteomic	discovery	 strategies	 (Crutchfild,	 Thomas,	 Sokoll,	
&	Chan,	2016).	To	our	knowledge,	only	one	proteomic	study	was	
previously	conducted	to	search	RLS	biomarkers	in	the	cerebrospi-
nal	 fluid	 (CSF)	 of	 RLS	 patients,	 identifying	 six	 candidate	 protein	
markers	for	the	early-	onset	of	RLS	(Patton	et	al.,	2013).	An	optimal	
biomarker	should	be	highly	sensitive	and	specific,	as	well	as	easily	
attainable,	with	a	not	invasive,	or	limited,	procedure	(Kohn,	Azad,	
Annunziata,	Dhamoon,	&	Whiteley,	2007).	CSF	sample	collection	
requires	 a	 more	 complex	 and	 potentially	 dangerous	 procedure	
than	blood,	that,	moreover,	represents	a	reasonable	source	of	bio-
markers	because	 it	 is	 directly	 exposed	 to	 all	 organs	of	 the	body	
and thus can be an archive of all ongoing processes.
The primary objective of our study was to analyze the plasma 
of	RLS	patients	in	comparison	with	healthy	control	subjects,	in	the	
search	 of	 potential	 diagnostic	 biomarkers	 of	 RLS,	 also	 consider-
ing the possible association with the disease severity. We applied 
proteomics methods based on two- dimensional gel electrophore-
sis	 (2-	DE)	 coupled	 to	 liquid	 chromatography-	mass	 spectrometry	
analysis.
2  | MATERIAL S AND METHODS
2.1 | Patients and controls selection
Primary	RLS	patients	(n	=	34)	and	healthy	subjects	as	control	group	
(n	=	17)	 from	 the	 medical	 staff	 were	 recruited	 at	 the	 Neurology	
Department	 of	 Bakirkoy	 Psychiatry	 and	 Neurology	 Research	 and	
Training	Hospital	Sleep	Disorders	Center	(Istanbul,	Turkey).
For	 all	 study	 participants,	 exclusion	 criteria	 were	 as	 follows:	
systemic	 or	 neurologic	 diseases,	 other	 diagnosed	 sleep	 disorders,	
anemia,	iron	deficiency,	uremia,	thyroid	disorders,	use	of	antidepres-
sants	and	antipsychotics,	excessive	alcohol	intake.
All	 patients	 were	 diagnosed	 as	 primary	 RLS	 according	 to	 the	
International	 Classification	 of	 Sleep	 Disorders	 diagnostic	 criteria	
(American	Academy	of	Sleep	Medicine,	2014),	while	the	degree	of	
RLS	severity	was	evaluated,	according	to	the	10-	item	International	
Restless	Legs	Syndrome	Study	Group	 (IRLSSG)	rating	scale,	as	fol-
lows:	mild	(IRLS	scores,	1–10),	moderate	(IRLS	scores,	11–20),	severe	
(IRLS	 scores	 21–30),	 and	 very	 severe	 (IRLS	 scores	 31–40)	 (Allen	
et	al.,	2014).
Based	on	 the	 results,	RLS	patients	were	divided	 into	 two	sub-
groups:	low-	medium	severity	(MMS)	group,	(n	=	17)	including	all	pa-
tients	with	mild	and	moderate	 IRLS	 scores,	 and	high	 severity	 (HS)	
group (n	=	17),	comprising	patients	with	severe	and	very	severe	IRLS	
scores	(Table	1).	Patients	and	control	groups	were	strictly	matched	
for	age	and	gender,	as	shown	in	Table	1.
The study received the approval of the local Ethical Committee 
and was carried out in conformity with the Helsinki Declaration. 
Informed consent to the study was provided by each subject.
2.2 | Patients rating scales
For	all	RLS	patients	were	also	evaluated:	(a)	the	level	of	depression	by	
the	Beck	Depression	Inventory	Score	(Beck,	Steer,	&	Carbin,	1988);	
(b)	the	quality	and	patterns	of	sleep	by	the	Pittsburgh	Sleep	Quality	
Index	 (PSQI)	 (Buysse,	 Reynolds,	 Monk,	 Berman,	 &	 Kupfer,	 1989);	 
(c)	the	daytime	sleepiness	and	tendency	to	sleep	during	the	day	by	
the	Epworth	Sleepiness	Scale	(ESS;	Izci	et	al.,	2008).
     |  3 of 9BELLEI Et aL.
2.3 | Plasma samples collection and treatment
Fasting	 morning	 venous	 blood	 was	 collected	 from	 both	 RLS	 pa-
tients	and	controls	into	EDTA	tubes.	Plasma	was	separated	by	cen-
trifugation,	aliquoted,	and	stored	frozen	at	−80°C	until	use.	Before	
proteomic	analysis,	plasma	samples	from	each	of	the	three	groups	
(controls,	MMS-	RLS	and	HS-	RLS)	were	combined	to	form	three	dif-
ferent pools per group.
Moreover,	in	biomarkers	discovery	studies,	depletion	strategies	
are necessary to decrease the high dynamic concentration range 
of	plasma	proteome,	allowing	 the	detection	of	 the	 low-	abundance	
component	fraction,	even	if	this	could	lead	to	the	concomitant	elim-
ination	of	nontargeted	proteins	(Bellei	et	al.,	2011).
In	this	work,	the	complexity	of	plasma	sample	was	reduced	by	
the	removal	of	albumin	and	IgG,	the	two	most	abundant	plasma	
proteins,	 using	 the	 ProteoPrep®	 Immunoaffinity	 Albumin	 and	
IgG	 Depletion	 Kit	 (Sigma),	 that	 specifically	 removes	 these	 pro-
teins	by	an	immunodepletion	method	(Bellei	et	al.,	2011).	Finally,	
total protein content was measured spectrophotometrically at λ 
595	nm.
2.4 | Two- dimensional gel electrophoresis (2- DE)
Protein separation was performed on depleted plasma samples 
by	 2-	DE,	 as	 previously	 described	 (Bellei	 et	al.,	 2017).	 Briefly,	
80 μg of protein was diluted with rehydration buffer and then 
loaded onto 7- cm- long immobilized pH gradient strips (Ready 
IPG	Strip™,	Bio-	Rad),	pH	range	3–10.	Afterward,	the	strips	were	
first subjected to isoelectric focusing and then to the second- 
dimension	separation	on	10%	polyacrylamide	gels,	 stained	with	
Coomassie	 Blue.	 The	 gel	 images	were	 acquired	 by	 a	 calibrated	
densitometer	 (GS-	800,	 Bio-	Rad)	 and	 analyzed	 by	 the	 PDQuest	
2-	D	 image	 analysis	 software	 (Bio-	Rad),	 as	 previously	 reported	
(Bellei	et	al.,	2017).
2.5 | Mass spectrometry analysis and protein 
identification
The	differentially	expressed	protein	spots	were	“in-	gel”	digested	
with	 trypsin,	 to	obtain	peptides	mixture	 to	be	analyzed	 through	
MS,	as	previously	described	(Bellei	et	al.,	2011).	The	concentrated	
peptides	were	 analyzed	 by	 a	 LC-	Chip-	MS	 System,	 composed	 of	
the	 Electrospray	 Ionization	 Quadrupole-	Time	 of	 Flight	 Mass	
Spectrometer	 (ESI-	Q-	ToF-	MS)	 (Accurate-	Mass	 G6520,	 Agilent	
Technologies)	 connected	 to	 a	 Nano	HPLC-	Chip	microfluidic	 de-
vice	(1200	Nano	HPLC-	Chip,	Agilent	Technologies).	The	MASCOT	
search	engine	(http://mascot.cigs.unimo.it/mascot),	together	with	
the	UniProt	 knowledgebase	 database,	was	 used	 for	 peptide	 se-
quence	searching.	The	highest	score	hits	among	MASCOT	search	
results	 were	 selected,	 and	 proteins	 were	 considered	 identified	
with	at	 least	 two	unique	peptides.	Moreover,	protein	 identifica-
tion	was	 repeated	at	 least	once,	using	spots	extracted	 from	dif-
ferent gel.
2.6 | Statistical analysis
The	 Student’s	 t test was used to compare demographic and clini-
cal	data	of	RLS	patients	and	control	subjects,	considering	a	p- value 
<0.05	as	statistically	significant.	All	reported	data	are	expressed	as	
mean ± standard deviation (SD).
Controls 
(n = 17)
MMS- RLS 
(n = 17)
HS- RLS  
(n = 17) p- Value
Age 44.5	±	7.0 45.1	±	11.0 44.6	±	6.9 0.941a
0.896b
Gender
Male 5	(29.4%) 7	(41.2%) 5	(29.4%) 1.000a
Female 12	(70.6%) 10	(58.8%) 12	(70.6%) 0.488b
RLS	onset
<3months — 2	(11.8%) 1	(5.9%) 0.463b
3months–1year — 2	(11.8%) 1	(5.9%)
1–5years — 5	(29.4%) 5	(29.4%)
>5years — 8	(47.0%) 10	(58.8%)
Iron parameters
Hemoglobin	(g/dl) — 13.9	±	1.3 13.7 ± 1.2 0.578b
Hematocrit	(%) — 41.4	±	6.0 41.6	±	3.6 0.923b
Mean	cell	volume	(fl) — 86.6	±	4.1 85.0	±	3.5 0.241b
Serum	iron	(μg/dl) — 113.3	±	69 78.7 ± 30.8 0.069b
Ferritin (μg/L) — 83.0	±	51.7 68.9	±	38.7 0.395b
Notes.	Age	data	and	iron	parameters	are	expressed	as	mean	±	standard	deviation.
p-	Value	based	on	the	Student’s	t test: aHS-	RLS	vs.	controls;	bHS-	RLS	vs.	MMS-	RLS	group.
TABLE  1 Demographic and clinical 
data	of	RLS	patients	and	controls
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3  | RESULTS
3.1 | Patients and controls data
Demographic	 information	 about	 RLS	 patients	 and	 controls	 are	
provided	in	Table	1.	As	evidenced,	no	significant	differences	con-
cerning	age	and	gender	were	detected	comparing	RLS	and	control	
groups.
According	to	the	severity	of	symptoms	assessed	by	the	IRLSSG	
rating	scale	for	RLS,	patients	were	divided	into	two	subgroups:	mild-	
moderate	severity	(MMS)	group	(17	patients,	50%)	and	high	severity	
(HS)	group	(17	patients,	50%).	In	Table	1	is	also	reported	the	RLS	du-
ration,	namely	the	onset	age	of	RLS	symptoms,	that	was	>5	years	for	
the	majority	of	patients,	in	both	RLS	groups	(47%	for	MMS	group	and	
58.8%	for	HS	group,	respectively).
The results obtained from the patients rating scales are illus-
trated	 in	 Figure	1.	 According	 to	 the	 Beck	 Depression	 Inventory	
Scale	 (Figure	1a),	 15	MMS-	RLS	patients	 (88%)	were	without	 de-
pression	symptoms	and	only	two	(12%)	presented	serious	depres-
sion,	while	in	HS	group	the	36%	of	patients	showed	mild-	serious	
depression.	 PSQI	 scores	 (Figure	1b)	 were	 significantly	 higher	 in	
HS	group	compared	to	MMS	group	(p	=	0.019),	indicating	that	HS-	
RLS	patients	had	worse	overall	sleep	quality.	Finally,	according	to	
the	ESS	(Figure	1c),	only	one	MMS-	RLS	patient	(6%)	received	>10	
points,	 reporting	excessive	daytime	 sleepiness,	 compared	 to	 the	
24%	(four	patients)	of	HS	group.
3.2 | Bidimensional gel electrophoresis and mass 
spectrometry analysis
The	2D-	gel	maps	were	 analyzed	by	 the	PDQuest	 image	analysis	
software,	after	a	normalization	step	to	correct	the	variability	due	
to	 the	 staining	 process.	 A	 total	 of	 15	 protein	 spots	were	 found	
differentially	expressed	between	RLS	and	controls	 (Figure	2).	All	
the	selected	spots	were	identified	by	ESI-	Q-	ToF-	MS	analysis;	the	
characterized	 proteins	 are	 listed	 in	 Table	2,	 wherein	 the	 alpha-
numeric annotation of each spot corresponds to that reported in 
Figure 2.
Notably,	 the	great	majority	of	spots	 (n	=	13)	was	recognized	as	
increased	in	RLS	groups	compared	to	controls,	while	only	two	spots	
resulted	decreased.	Specifically,	of	the	13	upregulated	spots,	eight	
resulted	increased	in	both	RLS	patient’s	groups,	and	corresponded	
to	 five	 unique	 proteins:	 alpha-	1B-	glycoprotein	 (A1BG),	 alpha-	1-	
acid	glycoprotein	1	(A1AG1),	haptoglobin	(HPT),	complement	C4-	A	
(CO4A),	and	immunoglobulin	kappa	constant	(IGKC).	In	Table	2	is	re-
ported	only	the	fold	change	value	calculated	in	MMS-	RLS/controls,	
because	 those	 obtained	 from	 HS-	RLS/controls	 were	 very	 similar,	
without significant differences.
F IGURE  1 Pie	charts	reporting	the	scores	obtained	from	the	rating	scales.	The	scores	achieved	for	MMS-	RLS	and	HS-	RLS	groups	are	
reported	in	percentage:	(a)	Beck	Depression	Inventory	Score,	(b)	Pittsburgh	Sleep	Quality	Index	(PSQI),	(c)	Epworth	Sleepiness	Scale	(ESS).	
p-	Value	obtained	by	the	Student’s	t test
53%
47%
18%
82%
Good sleep quality
Poor sleep quality
(b)   PSQI(a) Beck scale
MMS-RLS
group
HS-RLS
group
(c)   ESS
82%
12%
6%
41%
35%
24%
Normal
Acceptable
Excessive daytime sleepiness
88%
12%
64%12%
12%
12%
Normal
Serious depression
Medium depression
Mild mental distress
p = 0.172                                                p = 0.019                                            p = 0.096
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Five	spots,	corresponding	to	three	unique	proteins,	were	found	
upregulated	 only	 in	 HS-	RLS	 group:	 kininogen-	1	 (KNG1),	 immu-
noglobulin	 heavy	 constant	 alpha	 1	 (IGHA1),	 and	 immunoglobulin	
lambda	 constant	 2	 (IGLC2);	 this	 latter	 with	 the	 higher	 expression	
change	 vs.	 MMS-	RLS	 (+10.64),	 as	 shown	 in	 Table	2.	 Finally,	 one	
spot	resulted	downregulated	in	both	RLS	groups,	identified	as	com-
plement	C3	(CO3),	and	another	one	only	 in	HS-	RLS,	recognized	as	
alpha-	1-	antitrypsin	(A1AT).
4  | DISCUSSION
Nowadays,	the	causes	of	RLS	are	not	yet	completely	known	and	this	
makes	both	the	diagnosis	and	the	therapeutic	approach	quite	diffi-
cult. There is a great need for intensive basic and clinical research to 
discover	new	and	reliable	biomarkers,	useful	firstly	for	a	proper	diag-
nosis and afterward to develop more effective and specific medica-
tions	to	treat	RLS	symptoms.
In	the	present	study,	by	a	proteomic	approach,	we	found	an	ex-
pression	level	of	15	protein	spots,	corresponding	to	10	unique	pro-
teins,	significantly	altered	in	plasma	of	RLS	patients.
Specifically,	 one	 protein,	 A1AT,	 resulted	 decreased	 in	 HS-	RLS	
group	(Figure	2	and	Table	2).	Literature	data	show	a	correlation	be-
tween	A1AT	deficiency	and	CVD,	in	addition	to	musculoskeletal	co-
morbidities	(Duckers	et	al.,	2010;	Fähndrich	et	al.,	2017).	Circulating	
A1AT	has	a	protective	role	in	limitating	vascular	damage,	other	than	
to be involved in the regulation of vascular smooth muscle cells and 
control	 of	 inflammatory	 pathways.	 Low	 levels	 of	A1AT,	 leading	 to	
unopposed	neutrophil	elastase	activity	in	the	vascular	system,	may	
cause	the	local	degradation	of	elastin	and	the	consequent	increased	
F IGURE  2 Representative	2D	gel	maps.	(a)	Control	group,	(b)	MMS-	RLS	patients	group,	(c)	HS-	RLS	patients	group.	In	gel	images	are	
marked	the	protein	spots	significantly	different	among	the	three	groups,	identified	by	ESI-	Q-	ToF-	MS.	Panel	(a)	shows	the	decreased	
protein	spots,	panel	(b)	illustrates	the	spots	increased	in	both	RLS	groups	vs.	controls,	and	panel	(c)	the	spots	increased	in	HS-	RLS	group	vs.	
MMS-	RLS	and	control	groups.	Alphanumeric	codes	in	the	figures	correspond	to	those	listed	in	Table	2.	Each	gel	map	reports	the	molecular	
weight	(MW)	standard	protein	ladder,	expressed	in	kilodalton	(kDa)	(All	Blue	Precision	Plus	Protein™	Standards,	Bio-	Rad).	First	dimension	
separation:	IPG	strip,	pH	3–10.	Second-	dimension	separation:	10%	polyacrylamide	gels
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collagen	deposition.	This	condition,	especially	in	larger	central	arter-
ies,	may	induce	arterial	stiffness,	with	risk	to	develop	arteriosclerosis	
(Duckers	et	al.,	2010).	Our	 findings	could	suggest	a	greater	 risk	of	
CVD	especially	in	HS-	RLS	patients,	as	the	expression	level	of	A1AT	
was	four	times	lower	compared	to	controls	(Table	2).
Another	 protein,	 CO3,	 was	 found	 downregulated	 in	 both	 RLS	
groups vs. controls. Complement acts as a rapid and efficient im-
mune	 surveillance	 system,	 with	 different	 effects	 on	 both	 healthy	
and	altered	host	cells,	other	than	to	be	involved	in	homeostasis	con-
trol	and	 in	 inflammatory	processes	 (Ricklin,	Hajishengallis,	Yang,	&	
Lambris,	2010).	In	consequence,	defective	control	of	the	complement	
cascade,	or	of	its	regulation,	is	associated	with	several	disorders.	A	
decrease	of	CO3	 in	RLS	patients	 could	 substantially	 contribute	 to	
worsening	the	inflammatory	state	associated	with	RLS.	In	support	of	
this	assumption	is	the	further	finding	that	two	acute	phase	proteins,	
HPT	and	A1AG1,	have	been	found	overexpressed	 in	both	RLS	pa-
tient’s	groups.	As	evident	in	Figure	2,	spots	L4-	L6	(different	isoforms	
of	 the	 same	 protein),	 and	 spot	 L9	 (derived	 from	 protein	 fragmen-
tation),	were	 identified	 as	HPT	by	MS.	HPT	plasma	 concentration	
increases	several	folds	in	case	of	inflammatory	stimulus;	therefore,	it	
is strongly associated with diseases that have inflammatory sources 
(Quaye,	2008).	Moreover,	elevate	HPT	levels	have	been	observed	in	
CSF	of	patients	with	peripheral	neuropathy	that	causes	acute	neu-
romuscular	failure,	and	in	case	of	neuromyelitis	optica,	an	idiopathic	
flogistic	demyelinating	disease	of	the	CNS	predominantly	affecting	
optic	nerves	and	the	spinal	cord	(Bai	et	al.,	2009).
A1AG1,	or	orosomucoid,	is	a	glycoprotein	which	serum	concen-
tration	rises	several	folds	in	response	to	local	inflammatory	stimuli,	
systemic	tissue	injury,	or	infection	(Fournier,	Medjoubi-	N,	&	Porquet,	
2000).	 Its	biological	function	is	still	not	completely	established,	al-
though,	as	a	member	of	the	lipocalin	family,	it	has	binding	and	trans-
port	 activity,	 as	well	 as	 immunomodulatory	and	anti-	inflammatory	
roles	 (Hochepied,	 Berger,	 Baumann,	 &	 Libert,	 2003).	 The	 overex-
pression	 of	 A1AG1	 and	 HPT	 observed	 in	 plasma	 of	 RLS	 patients	
could suggest that these subjects are more sensitive to inflamma-
tion,	and	our	findings	may	be	a	response	to	the	inflammatory	com-
plaint	occurring	in	this	syndrome,	suggesting	the	possibility	that	RLS	
may	be	mediated,	or	negatively	affected,	by	a	condition	of	excessive	
inflammation.	In	a	proteomic	study	performed	on	CSF,	Patton	et	al.	
(2013)	have	found	downregulated	levels	of	A1AG,	which	reflect	the	
altered	iron	homeostasis	and	the	reduction	of	its	content	in	the	CNS	
of	RLS	patients.
In	our	work,	other	three	proteins,	A1BG,	CO4A,	and	 IGKC,	re-
sulted	 upregulated	 in	 both	 RLS	 group	 vs.	 controls,	 independently	
from	the	disease	severity	score	(Table	2).	A1BG	is	a	secreted	plasma	
protein and a member of the immunoglobulin superfamily with a rea-
sonable	role	 in	 the	 immune	system	and	 in	cell	adhesion	 (Halaby	&	
Mornon,	1998).	In	literature	are	reported	conflicting	data	concerning	
the	 expression	of	A1BG.	For	 example,	 in	 neuromyelitis	 optica	has	
been	found	a	reduced	expression	of	A1BG	in	CSF	of	patients	com-
pared	 to	 controls	 (Bai	 et	al.,	 2009).	Conversely,	 in	 case	of	 autoim-
mune	disorders,	which	frequently	are	associated	with	RLS,	Biswas	
et	al.	 (2013)have	 identified,	 by	 an	 immunoproteomic	 approach,	 a	
higher	expression	of	A1BG	 in	synovial	 fluid	of	patients	with	 rheu-
matoid	arthritis	(RA),	proposing	this	glycoprotein	as	a	biomarker	of	
diagnostic	importance	for	RA.
CO4A	has	a	central	role	in	the	activation	of	the	classical	pathway	
of	the	complement	system.	Moreover,	it	induces	the	contraction	of	
smooth	muscle	and	increases	vascular	permeability,	other	than	to	be	
a mediator of local inflammatory processes. This further strengthens 
our assumption of a great and significant presence of inflammation 
in	RLS.	A	recent	proteomic	study	ascribes	to	the	increase	of	CO4A	
in	CSF	a	negative	prognostic	role	for	multiple	sclerosis,	a	pathology	
often	associated	with	RLS	(Füvesi	et	al.,	2012).
Regarding	IGKC,	it	was	reported	increased	in	serum	of	patients	
with	autoimmune	diseases,	such	as	rheumatoid	arthritis	(Gottenberg	
et	al.,	 2007)	 and	 multiple	 sclerosis	 (Kaplan,	 Golderman,	 Yahalom,	
Yaskariev,	&	Sela,	2013),	and	 in	CSF	of	subjects	with	specific	CNS	
diseases,	like	neuromyelitis	optica	(Bai	et	al.,	2009).
In	addition	to	IGKC,	we	found	other	increased	immunoglobulins,	
IGHA1	e	IGLC2,	but	only	in	HS-	RLS	group	compared	to	MMS-	RLS	
and	controls	(Figure	2,	Table	2).	High	levels	of	immunoglobulins	im-
pact	on	processes	concerning	the	immune	system,	so	the	enhancing	
expression	of	immunoglobulins	in	RLS	at	high	severity	seems	to	in-
dicate a progressively greater involvement of immunological mech-
anisms	with	 the	worsening	of	 the	disease.	Noteworthy,	as	evident	
in	Table	2,	 IGLC2	 showed	 the	higher	 level	 of	 protein	 spot	 expres-
sion	 change	 vs.	MMS-	RLS	 group	 (+10.64).	A	massive	 upregulation	
of Ig- related genes was also observed by immunohistochemistry in 
cortical	sections	of	patients	with	multiple	sclerosis	(Torkildsen	et	al.,	
2010).
Finally,	another	protein	increased	only	in	HS	group	was	KNG1.	
This is a major component of plasma kallikrein- kinin system and a 
bradykinin	 precursor,	 a	 nanopeptide	with	 strong	 vasoactive	 and	
proinflammatory	 properties.	 Studies	 on	 KNG1-	deficients	 mice	
demonstrated an important role of this protein in the pathogen-
esis	 of	 autoantibody-	induced	 arthritis,	 proposing	 the	 block	 of	
KNG1	 cleavage	 as	 a	 novel	 therapeutic	 strategy	 for	 rheumatoid	
arthritis	 treatment	 (Xie,	 Dai,	 &	 Wu,	 2016).	 A	 study	 conducted	
in	mice	 recognized	 KNG1	 as	 a	 key	mediator	 of	 ischemic	 neuro-
degeneration and neuronal damage by increasing microvascular 
thrombosis,	blood–brain	barrier	leakage	and	inflammation;	KNG1	
inhibition allowed to protect from thromboembolic disorders and 
stroke	(Langhauser	et	al.,	2012).	In	humans,	extreme	levels	of	high-	
molecular- weight kininogen can potentiate the risk of myocardial 
infarction	 and	 ischemic	 stroke	 (Siegerink,	 Rosendaal,	 &	 Algra,	
2012).	Our	finding	of	increased	KNG1	amount	in	HS-	RLS	patients	
provides	a	 further	support,	 together	with	 the	downregulation	of	
A1AT,	for	a	greater	risk	of	CVD,	especially	in	RLS	at	high	severity.	
This	 is	 in	 line	with	 the	 literature,	 which	 proves	 the	 presence	 of	
a	close	 relationship	between	vascular	 risk	 factors,	CVD	and	RLS	
(Schlesinger,	Erikh,	Avizohar,	Sprecher,	&	Yarnitsky,	2009;	Winter	
et	al.,	 2013).	Moreover,	 it	 is	well	 known	 that	 inflammation	 plays	
a larger role in the predisposition to CVD and that stroke may be 
mediated	 by	 inflammatory	mechanisms.	Considered	 all	 together,	
our findings strongly support and consolidate the theoretical roles 
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of inflammatory mechanisms and immunological alterations pro-
posed	by	Weinstock,	Walters,	&	Paueksakon	(2012)	for	the	patho-
genesis	of	RLS.
In	the	last	few	years,	substantial	progress	has	been	made	also	in	
understanding	the	genetic	basis	of	RLS,	with	focus	on	the	identifi-
cation	of	genes	that	may	give	rise	to	the	disease	(Winkelmann	et	al.,	
2017).	 Genomewide	 association	 studies	 (GWAS),	 meta-	analysis,	
twin,	 and	 family	 large-	scale	 studies	 have	 successfully	 contributed	
to	 identify	 significant	 association	between	RLS	 and	 common	vari-
ants	 in	 MEIS1,	 BTBD9,	 and	MAP2K5	 genes	 (Thireau	 et	al.,	 2017;	
Winkelmann	et	al.,	2007).	It	should	be	noted	that	our	patients	were	
not	sequenced	for	these	allelic	variations	that	however	might	be	of	
relevant interest for the study.
Moreover,	another	important	consideration	is	that	13	of	17	pa-
tients	 in	the	MMS	group,	and	15	of	17	patients	 in	HS	group,	were	
under	 treatment	with	pramipexole	 (0.25–0.75	mg/day)	before	 col-
lecting	blood	samples,	and	only	one	patient	in	the	HS	group	was	tak-
ing	also	pregabalin	(150	mg/day).	We	believe	that	medications	could	
have	 an	 effect	 on	 proteomic	 analysis;	 hence,	 further	 studies	may	
enlighten the impact of pharmacological treatment on the plasmatic 
proteome.
Finally,	 relatively	 to	 the	 rating	 scales	 used	 in	 the	 study,	 we	
found	 a	 significantly	 poorer	 sleep	 quality	 in	 HS-	RLS	 vs.	 MMS	
group,	and	a	trend	toward	a	higher	daytime	sleepiness,	along	with	
a greater propensity toward symptoms of medium- severe depres-
sion	(Figure	1).
5  | CONCLUSIONS
In	summary,	 the	proteomic	analysis	of	plasma	from	RLS	patients	
revealed a defined protein cluster related to the involvement of 
biochemical networks principally linked to inflammatory and im-
mune	response;	specifically,	the	increasing	levels	of	immunoglob-
ulins may account for the progression and severity of the disease. 
Moreover,	 the	 underexpression	 of	 A1AT	 and	 the	 upregulation	
of	 KNG1	 are	 reflective	 of	 a	 greater	 risk	 for	 HS-	RLS	 patients	 to	
develop CVD; these proteins may represent potential early diag-
nostic biomarkers for cardiovascular and autoimmune disorders. 
Altogether,	 our	 data	 could	 suggest	 additional	 insights	 into	 the	
multifactorial	 pathophysiology	 of	 the	RLS	 and	 contribute	 to	 en-
hance the inflammatory/immunological hypothesis proposed for 
the	evolution	of	RLS	process.
The proteomic analysis of plasma allowed a greater understand-
ing	 of	 RLS,	 providing	 relevant	 information	 for	 its	 diagnosis	 and	
prognosis by the identification of a promising platform of candidate 
protein	biomarkers,	which	could	also	be	considered	as	helpful	drug	
targets to develop innovative treatment strategies.
This is a preliminary mass spectrometry- based proteomics study 
conducted	for	the	first	time	on	plasma	samples	from	RLS	patients,	so	
the	present	results	need	to	be	confirmed	and	extended	by	increasing	
the	number	of	cases,	also	applying	complementary	validation	tech-
niques	(such	as	western	blot	and	ELISA	test).
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